Claims for Patent: 6,956,027

Summary for Patent: 6,956,027

Title:	N-terminally chemically modified protein compositions and methods
Abstract:	Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel chemically modified G-CSF compositions and related methods of preparation.
Inventor(s):	Kinstler; Olaf B. (Thousand Oaks, CA)
Assignee:	Amgen Inc. (Thousand Oaks, CA)
Application Number:	10/264,846
Patent Claims:	1. An antiviral, pegylated consensus interferon. 2. The antiviral, pegylated consensus interferon of claim 1 that is an anti-hepatitis viral, pegylated consensus interferon. 3. The antiviral, pegylated consensus interferon of claim 1 that is an antihepatitis C viral, pegylated consensus interferon. 4. The anti-hepatitis C viral, pegylated consensus interferon of claim 3 wherein said consensus interferon is selected from from the group consisting of IFN-con.sub.1, IFN-con.sub.2, and IFN-con.sub.3. 5. The anti-hepatitis C viral, pegylated consensus interferon of claim 4 wherein said consensus interferon is IFN-con.sub.1. 6. The anti-hepatitis C viral, pegylated consensus interferon of claim 4 wherein said consensus interferon is IFN-con.sub.2. 7. The anti-hepatitis C viral, pegylated consensus interferon of claim 4 wherein said consensus interferon is IFN-con.sub.3. 8. The antiviral, pegylated consensus interferon of claim 1 that is an antiviral, monopegylated consensus interferon. 9. N-terminally pegylated consensus interferon. 10. N-terminally pegylated consensus interferon of claim 9 wherein said consensus interferon is selected from the group consisting of IFN-con.sub.1, IFN-con.sub.2, and IFN-con.sub.3. 11. N-terminally pegylated consensus interferon of claim 10 wherein said consensus interferon is IFN-con.sub.1. 12. N-terminally pegylated consensus interferon of claim 10 wherein said consensus interferon is IFN-con.sub.2. 13. N-terminally pegylated consensus interferon of claim 10 wherein said consensus interferon is IFN-con.sub.3. 14. N-terminally monopegylated consensus interferon. 15. A pharmaceutical composition comprising: (a) antiviral, pegylated consensus interferon; and (b) a pharmaceutically acceptable diluent, adjuvant or carrier. 16. The pharmaceutical composition of claim 15 that is essentially free of consensus interferon PEGylated at sites other than the N-terminus. 17. The pharmaceutical composition of claim 15 werein said consensus interferon is selected from the group consisting of IFN-con.sub.1, IFN-con.sub.2, and IFN-con.sub.3. 18. The pharmaceutical composition of claim 17 wherein said consensus interferon is IFN-con.sub.1. 19. The pharmaceutical composition of claim 17 wherein said consensus interferon is IFN-con.sub.2. 20. The pharmaceutical composition of claim 17 wherein said consensus interferon is IFN-con.sub.3. 21. The pharmaceutical composition of claim 15 wherein said consensus interferon is monopegylated. 22. A pharmaceutical composition comprising: (a) N-terminally pegylated consensus interferon; and (b) a pharmaceutically acceptable diluent, adjuvant or carrier. 23. The pharmaceutical composition of claim 22 that is essentially free of consensus interferon PEGylated at sites other than the N-terminus. 24. The pharmaceutical composition of claim 22 wherein said consensus interferon is selected from the group consisting of IFN-con.sub.1, IFN-con.sub.2, and IFN-con.sub.3. 25. The pharmaceutical composition of claim 24 wherein said consensus interferon is IFN-con.sub.1. 26. The pharmaceutical composition of claim 24 wherein said consensus interferon is IFN-con.sub.2. 27. The pharmaceutical composition of claim 24 wherein said consensus interferon is IFN-con.sub.3. 28. The pharmaceutical composition of claim 25 wherein said consensus interferon is monopegylated.